Health digital twins are defined as virtual representations (“digital twin”) of patients (“physical twin”) that are generated from multimodal patient data, population data, and real-time updates on patient and environmental variables. With appropriate use, HDTs can model random perturbations on the digital twin to gain insight into the expected behavior of the physical twin—offering groundbreaking applications in precision medicine, clinical trials, and public health. Main considerations for translating HDT research into clinical practice include computational requirements, clinical implementation, as well as data governance, and product oversight.
Generative AI is designed to create new content from trained parameters. Learning from large amounts of data, many of these models aim to simulate human conversation. Generative AI is being applied to many different sectors. Within healthcare there has been innovation specifically towards generative AI models trained on electronic medical record data. A recent review characterizes these models, their strengths, and weaknesses. Inspired by that work, we present our evaluation checklist for generative AI models applied to electronic medical records.
Digital health technologies (DHTs) have brought several significant improvements to clinical trials, enabling real-world data collection outside of the traditional clinical context and more patient-centered approaches. DHTs, such as wearables, allow the collection of unique personal data at home over a long period. But DHTs also bring challenges, such as digital endpoint harmonization and disadvantaging populations already experiencing the digital divide. A recent study explored the growth trends and implications of established and novel DHTs in neurology trials over the past decade. Here, we discuss the benefits and future challenges of DHT usage in clinical trials.
The U.S. Food and Drug Administration’s (FDA) recent authorization of DermaSensor, an AI-enabled device for skin cancer detection in primary care, marks a pivotal moment in digital health innovation. Clinically, the authorization of the first AI-enabled device for use by non-specialists for detecting skin cancer reinforces the feasibility of digital health technologies to bridge gaps in access and expertise in medical practice. The authorization also establishes a new regulatory precedent for FDA authorization of medical devices incorporating AI and machine learning (ML) technologies within dermatology. Together, this article uses the DermaSensor authorization to examine the clinical evidence and regulatory implications of emerging AI-enabled technologies in dermatology.
The utilization of artificial intelligence (AI) in diabetes care has focused on early intervention and treatment management. Notably, usage has expanded to predict an individual’s risk for developing type 2 diabetes. A scoping review of 40 studies by Mohsen et al. shows that while most studies used unimodal AI models, multimodal approaches were superior because they integrate multiple types of data. However, creating multimodal models and determining model performance are challenging tasks given the multi-factored nature of diabetes. For both unimodal and multimodal models, there are also concerns of bias with the lack of external validations and representation of race, age, and gender in training data. The barriers in data quality and evaluation standardization are ripe areas for developing new technologies, especially for entrepreneurs and innovators. Collaboration amongst providers, entrepreneurs, and researchers must be prioritized to ensure that AI in diabetes care is providing quality and equitable patient care.
Artificial intelligence (AI) and natural language processing (NLP) have found a highly promising application in automated clinical coding (ACC), an innovation that will have profound impacts on the clinical coding industry, billing and revenue management, and potentially clinical care itself. Dong et al. recently analyzed the technical challenges of ACC and proposed future directions. Primary challenges for ACC exist at the technological and implementation levels; clinical documents are redundant and complex, code sets like the ICD-10 are rapidly evolving, training sets are not comprehensive of codes, and ACC models have yet to fully capture the logic and rules of coding decisions. Next steps include interdisciplinary collaboration with clinical coders, accessibility and transparency of datasets, and tailoring models to specific use cases.